CARYN ECKER: Open Payments
NPI 1427351063 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,125 in 48 payments from 23 companies in 2025. Trend: 2023 $874 · 2024 $1,695 · 2025 $1,125
Food & beverage: $1,026Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $191 |
| Celgene Corporation | 8 | $157 |
| PFIZER INC. | 5 | $102 |
| ARRAY BIOPHARMA INC | 4 | $73 |
| AstraZeneca Pharmaceuticals LP | 3 | $66 |
| Gilead Sciences, Inc. | 2 | $61 |
| Rigel Pharmaceuticals, Inc. | 2 | $52 |
| ABBVIE INC. | 2 | $49 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| GENZYME CORPORATION | 1 | $35 |
Products named: REBLOZYL, RYBREVANT, OPDIVO, BOSULIF, Trodelvy, DARZALEX, TAVALISSE, BRAFTOVI.
Industry payments across NY — which companies pay providers there.
